Skip to main content
Erschienen in: Reactions Weekly 1/2018

01.06.2018 | Clinical study

Alemtuzumab-induced thyroid dysfunction examined

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

Thyroid dysfunction (TD) occurs frequently in multiple sclerosis (MS) patients treated with alemtuzumab − with Grave's disease (GD) being the most common form, say UK researchers. …
Literatur
Zurück zum Zitat Pariani N, et al. Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features. Journal of Clinical Endocrinology and Metabolism : [15 pages], 6 Jun 2018. Available from: URL: http://dx.doi.org/10.1210/jc.2018-00359 Pariani N, et al. Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features. Journal of Clinical Endocrinology and Metabolism : [15 pages], 6 Jun 2018. Available from: URL: http://​dx.​doi.​org/​10.​1210/​jc.​2018-00359
Metadaten
Titel
Alemtuzumab-induced thyroid dysfunction examined
Publikationsdatum
01.06.2018
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-018-48095-9

Weitere Artikel der Ausgabe 1/2018

Reactions Weekly 1/2018 Zur Ausgabe

Case report

Resorcinol

Case report

Pazopanib

Case report

Capecitabine